Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study

Osuga Y, Yutaka Osuga, Fujimoto-Okabe H, Haruka Fujimoto-Okabe, Atsushi Hagino, Hagino A
Fertility and sterility · 2017 · vol. 108(4) , pp. 673–678 · doi:10.1016/j.fertnstert.2017.07.021 · PMID:28911934 · W2752545486
article OA: bronze CC0 ⤵ 90 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This randomized, double-blind, multicenter, placebo-controlled study evaluated the efficacy and safety of dienogest in treating painful symptoms associated with adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo evaluate the efficacy and safety of dienogest (DNG), a progestational 19-norsteroid, in patients with symptomatic adenomyosis.DesignPhase III, randomized, double-blind, multicenter, placebo-controlled study.SettingClinical study sites in Japan.Patient(s)Sixty-seven patients with adenomyosis.Intervention(s)Patients were randomly assigned to receive DNG (2 mg/d, orally) or placebo for 16 weeks. In cases of complicated anemia, patients were treated for anemia before randomization.Main outcome measure(s)The primary end point was the change from baseline to after treatment pain score, using zero- to three-point verbal rating scales that defined pain severity according to limited ability to work and need for analgesics. The visual analogue scale was used as another pain parameter.Result(s)Decreases from baseline in the pain score and the visual analogue scale at the end of treatment were significantly more in the DNG group than in the placebo group (P<.001). During the treatment period, almost all of the patients treated with DNG experienced irregular uterine bleeding and one patient had mild anemia. No severe cases of anemia were observed.Conclusion(s)These results suggest that DNG is effective and well tolerated in the treatment for painful symptoms associated with adenomyosis not complicated by severe uterine enlargement or severe anemia.Clinical trial registration numberJapicCTI-142642(en).

My notes (saved in your browser only)

Condition tags

chronic_pelvic_painadenomyosis

MeSH descriptors

Adenomyosis Nandrolone Pelvic Pain Adenomyosis Adenomyosis Adult Double-Blind Method Female Humans Japan Menstruation Disturbances Menstruation Disturbances Menstruation Disturbances Middle Aged Nandrolone Nandrolone Pain Measurement Pelvic Pain Pelvic Pain Placebos

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:13.663096+00:00
License: CC0 · commercial use OK